Cargando…
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
Hypoxia contributes to resistance of tumors to some cytotoxic drugs and to radiotherapy, but can in principle be exploited with hypoxia-activated prodrugs (HAP). HAP in clinical development fall into two broad groups. Class I HAP (like the benzotriazine N-oxides tirapazamine and SN30000), are activa...
Autores principales: | Foehrenbacher, Annika, Secomb, Timothy W., Wilson, William R., Hicks, Kevin O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873531/ https://www.ncbi.nlm.nih.gov/pubmed/24409417 http://dx.doi.org/10.3389/fonc.2013.00314 |
Ejemplares similares
-
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
por: Foehrenbacher, Annika, et al.
Publicado: (2013) -
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018) -
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021) -
Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020) -
Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling
por: Jackson-Patel, Victoria, et al.
Publicado: (2022)